Chinese Peripheral Vascular Device Market Will Grow At About 10 Percent Annually Through 2022 Aortic Stent Grafts Will Continue To Generate the Majority of Revenues Due To Strong Acceptance in the Thoracic Indication, According to Decision Research Group
BURLINGTON, Mass., Feb. 13, 2014 /PRNewswire/ -- Decision Resources Group finds that the Chinese peripheral vascular (PV) device market will grow strongly through 2022 as patients in China increasingly seek treatment for PV disease. Historically, awareness of the disease among patients and physicians was low, resulting in a large, undiagnosed patient population. However, initiatives by manufacturers and physician societies will spread awareness of the disease over the next few years, driving demand for the relevant procedures. Combined with continuing economic expansion and healthcare infrastructure improvements, more patients will undergo PV treatments going forward.
"The highly anticipated approval of drug-coated balloons (DCBs), expected in 2015, will also help to spur growth in the Chinese PV device market," said Decision Resources Group Analyst Darren Lin. "These premium-priced products show promise for the lower-extremity indications, such as the femoropopliteal and infrapopliteal arteries, and they will become commonplace in large cities like Beijing and Shanghai by 2022. However, DCBs will face some competition from drug-eluting stents, which will enter the market around the same time."
Several practice patterns distinguish China from its neighbors. The use of carotid stenting over carotid endarterectomy is much more common in China, supporting the markets for carotid stents and embolic protection devices. More notably, penetration of thoracic endovascular repair into surgical repair is high in China, especially in comparison to countries such as Japan and South Korea. This is largely because of the high proportion of patients in China suffering from thoracic aortic dissections, which has spurred local manufacturers such as MicroPort Medical to design stent grafts with this specific indication in mind. As a result, the Chinese thoracic aortic stent graft market was worth nearly $140 million in 2013, only slightly lower than the value of the market in the U.S.
Decision Resources Group's Chinese Markets for Peripheral Vascular Devices 2014 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for PV stents, percutaneous transluminal angioplasty balloon catheters, embolic protection devices, inferior vena cava filters, aortic stent grafts, synthetic surgical grafts and PV accessory devices in the province-level municipalities, as well as the east coast, central, and other regions of China. A current-year snapshot is also shown by hospital tier and city tier.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources Group